Author: Ravi Shankar

ATLANTA, Oct. 26, 2026 (GLOBE NEWSWIRE) — Gray Media today named Jennifer Rieffer as the new General Manager of WBTV (CBS) in Charlotte, North Carolina (DMA 21), effective November 16th.

A graduate of Morehead State University, Rieffer started her broadcast career in Lexington, Kentucky, where she spent 24 years at the Fox affiliate. She then moved to Flint, Michigan, where she served as General Manager overseeing the Fox, NBC, and CW stations.

In 2021, Rieffer joined WXIX FOX19 in Cincinnati. Since her arrival, she has been instrumental in WXIX becoming the official Flagship station of the Cincinnati Bengals and the over-the-air partner of the Cincinnati Reds.

About Gray Media:

Gray Media, Inc. (NYSE: GTN) is a multimedia company headquartered in Atlanta, Georgia. We are the nation’s largest owner of top-rated local television stations and digital assets. We serve 117 full-power television markets that collectively reach approximately 37% of US television households. The portfolio includes 78 markets with the top-rated television station and 101 markets with the first and/or second highest rated television station in average all-day ratings across the 116 of such markets that were measured by Nielsen in 2025. We also own the largest Telemundo Affiliate group with 46 markets and Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with the most advanced digital products and services. Our additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios.

Gray Contact:

Sandy Breland, Executive Vice President, Chief Operating Officer, 404-266-8333

#         #        #

Company announcement
No. 66/2026

                                                 26 October 2026

Transactions in connection with share buyback programme
On 3 February 2026, Netcompany Group A/S (“Netcompany”) announced that a share buyback programme of up to DKK 750m and a maximum of 3,250,000 shares had been initiated with the purpose of adjusting Netcompany’s capital structure and meeting its obligations relating to share-based incentive programmes.

The share buyback programme is executed in accordance with EU Market Abuse Regulation, EU Regulation no. 596/2014 of 16 April 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Regulation”). The share buyback programme will end no later than 29 January 2027.

Transactions made under the share buyback programme will be announced through Nasdaq Copenhagen on a weekly basis.

The following transactions have been executed in the period 19 October 2026 to 23 October 2026:

	Number of shares	Average purchase price, DKK	Transaction value, DKK
19/10/2026	2,000	375.40	750,799
20/10/2026	9,801	381.45	3,738,545
21/10/2026	1,953	377.77	737,784
22/10/2026	11,139	384.29	4,280,653
23/10/2026	18,107	385.03	6,971,648
Accumulated for the period	43,000	–	16,479,429
Accumulated under the programme	1,641,712	–	545,222,159

Detailed information on all transactions under the share buyback programme during the period is included in the attached appendix.

Following the above transactions and vesting of restricted share units, Netcompany owns a total of 1,985,290 treasury shares corresponding to 4.3% of the total share capital.

Additional information
For additional information, please contact:

Netcompany Group A/S
Thomas Johansen, CFO, +45 51 19 32 24
Frederikke Linde, Head of IR, +45 60 62 60 87

Attachments

• 66. Netcompany – Transactions in connection with share buyback programme
• 66. Appendix – Information on all transactions

BRISBANE, Australia, Oct. 26, 2026 (GLOBE NEWSWIRE) — North American lithium producer Elevra Lithium Limited (“Elevra” or “Company”) (ASX:ELV; NASDAQ:ELVR) is pleased to announce that it has completed the sale of all of its rights and interests in the Ewoyaa Lithium Project (“Ewoyaa Project”) in Ghana to Zhejiang Huayou Cobalt Co., Ltd. (“Huayou”), as announced on 11 May 2026¹ and 1 October 2026².

Completion of the sale follows the receipt of the required Ghanaian Government approvals, and Elevra received cash consideration of US$71 million before fees and taxes. The sale includes all of Elevra’s rights and interests in the Ewoyaa Project, including its spodumene concentrate offtake rights. Additionally, Elevra no longer has any funding commitment to develop the Ewoyaa Project.

The sale allows Elevra to sharpen its focus on core North American assets, and proceeds from the sale will provide Elevra with additional financial flexibility as the Company advances the North American Lithium brownfield expansion, development activities at Moblan and other growth projects.

Separately, Huayou continues to progress its proposed acquisition of Atlantic Lithium³ which holds the remaining private-sector interest in the Ewoyaa Project. Huayou’s acquisition of Elevra’s interests in the Ewoyaa Project is separate from, and is not conditional upon, completion of Huayou’s proposed acquisition of Atlantic Lithium.

Elevra’s Managing Director and Chief Executive Officer, Mr. Lucas Dow, said: “Completing the sale of our Ewoyaa interest to Huayou delivers our goal of improving our financial flexibility while removing the development funding obligations attached to the project and simplifying our portfolio.

“With the proceeds now received, we are well placed to advance our North American lithium assets. I would like to thank the Ghanaian authorities for their engagement through the approvals process, Huayou for working constructively with us to reach completion, and Atlantic Lithium for its support of the transfer.”

Announcement authorised for release by Elevra’s Managing Director and Chief Executive Officer.

_____________________________________

¹ See ASX announcement dated 11 May 2026 “Elevra enters agreement to sell Ewoyaa Project Interest”.
² See ASX announcement dated 1 October 2026 “Ewoyaa Sale Update”.
³ Atlantic Lithium ASX announcement dated 7 May 2026, “Binding Scheme Implementation Deed with Huayou”.

About Elevra Lithium

Elevra Lithium Limited is a North American lithium producer (ASX:ELV; NASDAQ:ELVR) with projects in Québec, Canada, United States, and a joint venture in Western Australia.

Elevra’s assets comprise North American Lithium (100%), a 60% stake in the Moblan Lithium Project in Central Québec and the Carolina Lithium Project (100%) in the United States.

For more information, please visit us at www.elevra.com

For more information, please contact:

Andrew Barber

Investor Relations

PH: +617 3369 7058

DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) — Kraig Biocraft Laboratories (OTCQB: KBLB) is moving beyond the science of spider silk and into the business of making it matter.

For years, commercial spider silk represented one of biotechnology’s most tantalizing challenges: reproduce a remarkable natural material, manufacture it at meaningful scale, and turn its extraordinary properties into products customers will actually buy. Now, Kraig Labs is building a case that this once-elusive vision can become a commercial reality.

The company’s latest move, launching a performance-yarn development program while shipping recombinant spider silk samples to an innovator with experience collaborating with top-tier aerospace manufacturers, signals an important shift. The challenge is no longer simply producing the material. It is engineering the yarns, blends, and fabric constructions that can bring its properties into the marketplace.

The groundwork is already being laid. In September, Kraig Labs announced its first commercial spider silk yarn shipment to a globally recognized performance sportswear brand. That initial order marked a critical transition from producing a novel biomaterial to delivering a customer-specific product. The new development program builds directly on that milestone, opening potential pathways into advanced apparel, technical textiles, and other demanding applications.

As CEO and founder Kim Thompson put it: “Our first custom yarn showed that it is now possible to produce and deliver spider silk to industry.”

That statement captures the significance of the moment. A technology that once seemed to belong to the distant future is now being processed into yarn, shipped to customers, and presented to specialists capable of evaluating its potential in sophisticated material systems.

Production advances add weight to the story. Kraig Labs reported nearly 2.5 metric tons of recombinant spider silk cocoons from a single production cycle in June, followed by another production record in August. In October, the company reported that all three production centers were operating as commercial deliveries began to take hold. These developments suggest that scaling the biological platform and building a commercial pipeline are increasingly interconnected priorities.

The company’s appearance on the cover of National Geographic in March also brought international attention to the science behind its approach: genetically engineered silkworms producing spider silk proteins, harnessing the scalability of silkworm cultivation to pursue the performance potential of spider silk.

What’s next?

The market will be watching for further details on the company’s recent shipments, including updates on the materials delivered, the timing and destination of subsequent batches, and whether additional customers or commercial orders emerge. This data could help clarify how Kraig Labs is converting customer interest into a repeatable commercial pipeline.

Project Atlas is another important development to watch. Future updates on the project’s progress, milestones, and potential commercial implications could provide additional insight into the company’s broader strategy as it works to expand its reach beyond initial yarn sales.

The direction is becoming clearer: Kraig Labs is expanding its efforts beyond producing spider silk toward designing materials around it, with multiple potential routes to commercialization. Every new yarn construction and material blend could broaden the range of products the company can pursue.

The breakthrough is no longer just the possibility of making spider silk. It is the growing ability to turn that biology into an industrial material. If Kraig Labs can translate its production progress and customer engagements into repeat business, the company could be approaching a defining transition, from biotechnology pioneer to supplier of a new class of performance materials.

The science opened the door. Commercial execution will determine how far it leads.

About 24/7 Market News

In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

Industrial food-production facility adopts Beyond Oil as part of its standard frying operations, marking the Company’s first commercial adoption in the industrial-frying segment

VANCOUVER, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) — Beyond Oil Ltd. (TSX: BOIL) (OTCQB: BEOLF) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing health risks associated with fried food while improving food quality, lowering operational costs, minimizing waste and enhancing sustainability, today announced that the industrial food-production facility that hosted the Company’s independent industrial-scale pilot has adopted Beyond Oil’s patented technology as part of its standard frying operations, marking the Company’s first commercial adoption in the industrial-frying segment.

The pilot integrated Beyond Oil’s patented product into the facility’s existing filtration workflow and delivered approximately 93% lower Free Fatty Acids and approximately 52% lower Total Polar Compounds versus an untreated control across the full production cycle, representing the first validated application of the Company’s chemistry in an industrial-frying environment.

The facility has completed implementation of Beyond Oil’s patented technology into its existing frying operations and adopted it as part of its standard operating procedures. The Company’s near-term commercial focus remains on accelerating growth in its core foodservice and food retail businesses, particularly through direct sales in the U.S. market, while this first industrial adoption demonstrates its ability to translate successful industrial-scale validation into commercial implementation.

The industrial-frying segment represents a significant new vertical for the Company, exposing its technology to a large and growing market in which operators face tightening regulatory limits on frying-oil composition and increasing attention to worker exposure to frying-oil emissions.

“When we announced the successful completion of our industrial-scale pilot in August, we demonstrated that our technology works in an industrial frying environment. Today, we have taken the next step, with our first industrial customer completing implementation and adopting Beyond Oil as part of its standard frying operations. This is an important milestone for us, giving us our first real foothold in a vast market and, more importantly, the opportunity to gain deeper insights into the needs and challenges of industrial food manufacturers, allowing us to continue developing and adapting our solutions for this segment. While our immediate focus remains on driving continued growth in our core foodservice and food retail businesses, we are already actively advancing strategic opportunities in industrial frying that have the potential to create meaningful long-term value for Beyond Oil,” said Jonathan Or, CEO of Beyond Oil.

The industrial-frying segment is a sizable potential market for Beyond Oil. The global potato chips market alone is projected to reach approximately US$55 billion by 2030, and the global frozen French fries market approximately US$58 billion by 2030, both produced through industrial frying¹. The Company believes this first commercial adoption positions it to participate in that market as operators seek to extend frying-oil life, strengthen quality control and reduce costs.

About Beyond Oil Ltd.

We all love fried food. Let’s make it better. Not by changing what people love. By improving the system behind it. Beyond Oil Ltd. (TSX: BOIL, OTCQB: BEOLF) is a food-tech innovation company on a mission to help foodservice operators improve fried food across every dimension that matters: quality, health, consistency, safety, sustainability and profitability. We achieve these outcomes by improving the system behind every kitchen, the frying performance and oil management that determine what lands on the plate. The Company’s patented technology, cleared by the FDA and Health Canada, integrates into existing kitchen workflows to improve frying performance and oil management, helping operators deliver more consistent food, strengthen operational control and reduce oil waste. Beyond Oil’s solution serves restaurant chains, supermarkets, hotels, catering, institutions and industrial frying operations worldwide, turning frying into a measurable, repeatable and scalable brand standard. The result is a better frying standard, helping every fryer, every shift and every plate live up to the food people love. For more information, please visit: www.beyondoil.co.

Forward-Looking Statements and Information

This news release contains “forward-looking statements” within the meaning of the U.S. Securities Act of 1933, the U.S. Securities Exchange Act of 1934, “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of other relevant securities legislation, including applicable securities laws in Canada, which reflect Beyond Oil Ltd.’s current views with respect to, among other things, its operations and financial performance (collectively, “forward-looking statements”). Forward-looking statements include statements that are predictive in nature, depend upon or refer to future results, events or conditions, and include, but are not limited to, statements which reflect management’s current estimates, beliefs and assumptions and which are in turn based on our experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. The estimates, beliefs and assumptions of Beyond Oil Ltd. are inherently subject to significant business, economic, competitive and other uncertainties and contingencies regarding future events and as such, are subject to change. Forward-looking statements are typically identified by words such as “expect”, “anticipate”, “believe”, “foresee”, “could”, “estimate”, “goal”, “intend”, “plan”, “seek”, “strive”, “will”, “may” and “should” and similar expressions. In particular, this news release contains forward-looking statements regarding: the facility’s adoption and implementation of the Company’s technology as part of its standard frying operations and the expected scope and timing of such implementation; the Company’s ability to convert this first industrial adoption into broader commercial adoption or recurring revenue within the industrial-frying segment; the Company’s advancement of additional strategic opportunities in industrial frying and its ability to create meaningful long-term value in the segment; the continued expansion of the Company’s core foodservice and direct-sales business in the United States; and the long-term significance and potential of the industrial-frying opportunity for the Company. Forward-looking statements are subject to specific risks and uncertainties, including: this first industrial adoption may not lead to additional customers, recurring revenue or a broader commercial relationship with the facility’s operator; the Company’s additional strategic opportunities in industrial frying may not progress or result in commercial adoption or meaningful value for the Company; customer adoption within the industrial-frying segment may proceed more slowly than anticipated or may not materialize as expected; the Company’s continuing primary focus on its core foodservice business may limit the near-term revenue contribution of the industrial-frying segment; and the market for industrial-frying solutions may not develop in line with the Company’s expectations. Although Beyond Oil Ltd. believes that such forward-looking statements are based upon reasonable estimates, beliefs and assumptions, certain factors, risks and uncertainties, which are described from time to time in our documents filed with the securities regulators in the USA and Canada, as well as factors not presently known to Beyond Oil Ltd. or that Beyond Oil Ltd. currently believes are not material, could cause actual results to differ materially from those contemplated or implied by forward-looking statements. Readers are urged to consider these risks, as well as other uncertainties, factors and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements, which are based only on information available to us as of the date of this news release. Except as required by law, Beyond Oil Ltd. undertakes no obligation to publicly update or revise any forward-looking statements, whether written or oral, that may be as a result of new information, future events or otherwise.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Company Contact:
Adi Olesker, VP of Investor Relations
Phone: +972-50-694-2517
adio@beyondoil.co

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
BOIL@arxhq.com

¹ Knowledge Sourcing, Potato Chips Market (projected to reach US$55.07 billion by 2030). Available at: https://www.knowledge-sourcing.com/resources/press-releases/potato-chips-market; The Insight Partners, Frozen French Fries Market (projected to reach US$57.91 billion by 2030). Available at: https://www.theinsightpartners.com/reports/frozen-french-fries-market

REDWOOD CITY, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) — Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2026 financial results will be released on Monday, November 9, 2026. Starting at 5:00 p.m. Eastern Daylight Time on November 9, 2026, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call.

Conference Call Information

When: Monday, November 9, 2026, starting at 5:00 p.m. Eastern Daylight Time.

To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.media-server.com/register/BI55798b5af6004203b3a31cfe6dff187e

Webcast: https://edge.media-server.com/mmc/p/qhta3pue

The press release with the third quarter 2026 financial results and related materials will be available at https://investors.coherus.com before the start of the conference call.

A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations.

Please dial in15 minutes early to ensure a timely connection to the call.

Disclosure Information

Coherus uses the https://investors.coherus.com website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. 

About Coherus Oncology

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI^® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, prostate, head & neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in R/M Nasopharyngeal Carcinoma and advance the development of its two pipeline candidates in combination with LOQTORZI and through strategic partnerships.

Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and improve outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors; including head and neck squamous cell carcinoma, colorectal cancer, gastric, gastro-esophageal-junction, esophageal adenocarcinoma and esophageal squamous cell carcinoma. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.

LOQTORZI^® is a registered trademark of Coherus Oncology, Inc.
©2026 Coherus Oncology, Inc. All rights reserved.

Coherus Oncology Contact Information:

For Investors:
Carrie Graham
Vice President, Investor Relations & Advocacy
IR@coherus.com

MCLEAN, Va., Oct. 26, 2026 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) today announced that it has commenced a fixed-price cash tender offer (the “Offer”) for the purchase of any and all of the STACR^® (Structured Agency Credit Risk) Notes listed in the table below (the “Notes”) beginning Monday, October 26, 2026. Each of the classes of Notes subject to the Offer was issued by the STACR Trust identified in the table below (each, a “Trust”). Freddie Mac is the holder of the owner certificate issued by each Trust and, as a result, the sole beneficial owner of each Trust.

Freddie Mac has engaged Wells Fargo Securities, LLC and Cantor Fitzgerald & Co. as lead dealer managers (the “Lead Dealer Managers”) and CastleOak Securities, L.P. as co-dealer manager (the “Co-Dealer Manager” and, collectively with the Lead Dealer Managers, the “Dealer Managers”) for the Offer. Freddie Mac is offering to purchase any and all of the Notes listed. The applicable Total Consideration to be paid by Freddie Mac to holders that tender Notes accepted for purchase pursuant to the Offer will be calculated based on the original principal amount of such tendered and accepted Notes, the applicable factor, and the applicable Tender Offer Consideration identified in the table below, plus any accrued and unpaid interest under the applicable Indenture upon the terms and subject to the conditions set forth in the Offer to Purchase dated October 26, 2026 (as amended from time to time, the “Offer to Purchase”). Capitalized terms used and not otherwise defined herein will have the meaning ascribed to such terms in the Offer to Purchase.

The tender offer period will commence on Monday, October 26, 2026, and expire at 5 p.m., New York City time, on Friday, October 30, 2026 (the “Expiration Time”), unless extended. Holders must validly tender their Notes at or prior to the Expiration Time. Notes validly tendered may be withdrawn at any time at or prior to 5 p.m., New York City time, on Friday, October 30, 2026, unless extended by Freddie Mac, but not thereafter (except in certain limited circumstances where additional withdrawal rights are granted by Freddie Mac or otherwise required by law).

Holders whose Notes are purchased in the Offer will receive accrued and unpaid interest from the last interest payment date to, but not including, the Settlement Date (as defined in the Offer to Purchase) for the Notes. Freddie Mac expects the Settlement Date to occur on Tuesday, November 3, 2026.

Title of Security	STACR Trust	CUSIP Number (Rule 144A / Regulation S)	ISIN Number (Rule 144A / Regulation S)	Original  Principal Amount		Tender Offer Consideration (per $1,000  original principal  amount)
STACR 2020-HQA5 B-1	Freddie Mac STACR REMIC Trust 2020-HQA5	35565TBD0 / U3197KBD0	US35565TBD00 / USU3197KBD01	$225,000,000		$1,096.25
STACR 2021-DNA3 B-1	Freddie Mac STACR REMIC Trust 2021-DNA3	35564KFG9 / U3201WFG7	US35564KFG94 / USU3201WFG79	$211,000,000		$1,135.00
STACR 2021-DNA5 B-1	Freddie Mac STACR REMIC Trust 2021-DNA5	35564KJA8 / U3201WJA6	US35564KJA88 / USU3201WJA63	$339,000,000		$1,064.90
STACR 2021-HQA1 B-1	Freddie Mac STACR REMIC Trust 2021-HQA1	35564KCN7 / U3201WCN5	US35564KCN72 / USU3201WCN57	$223,000,000		$1,110.00
STACR 2023-DNA2 M-1B	Freddie Mac STACR REMIC Trust 2023-DNA2	35564KT66 / U3201WT56	US35564KT664 / USU3201WT560	$127,000,000		$1,035.17

This announcement is neither an offer to buy nor a solicitation of offers to buy any of these securities. None of Freddie Mac, the Dealer Managers, or the Information Agent make any recommendation that any holder of the securities tender or refrain from tendering all or any portion of the original principal amount of such holder’s securities. Holders must make their own decisions whether to tender securities, and if so, decide on the original principal amount of securities to tender.

The Offer is being made only upon the terms and subject to the conditions set forth in the Offer to Purchase. Copies of the Offer to Purchase may be obtained on Freddie Mac’s website at https://capitalmarkets.freddiemac.com/crt/securities or from the Information Agent for the Offer, Global Bondholder Services Corporation’s website at https://www.gbsc-usa.com/FreddieMac, or by calling (212) 430-3774 or (855) 654-2015 (toll-free). Questions regarding the Offer may be directed to Wells Fargo Securities, LLC at (704) 410-4820 or (866) 309-6316 (toll-free); Cantor Fitzgerald & Co. at (212) 610-2220; or Global Bondholder Services Corporation, as tender agent, at (212) 430-3774 or (855) 654-2015 (toll-free).

This announcement does not constitute an invitation to participate in the Offer in or from any jurisdiction in or from which, or to or from any person to or from whom, it is unlawful to make such Offer under applicable securities laws or otherwise. The distribution of materials relating to the Offer, and the transactions contemplated by the Offer, may be restricted by law in certain jurisdictions where it is legal to do so. The Offer is void in all jurisdictions where it is prohibited. If materials relating to the Offer come into your possession, you are required by Freddie Mac to inform yourself of and to observe all of these restrictions. The materials relating to the Offer do not constitute, and may not be used in connection with, an offer or solicitation in any place where offers or solicitations are not permitted by law. If a jurisdiction requires that the Offer be made by a licensed broker or dealer and a dealer manager or any affiliate of a dealer manager is a licensed broker or dealer in that jurisdiction, the Offer shall be deemed to be made by the dealer manager or such affiliate on behalf of Freddie Mac in that jurisdiction.

About Freddie Mac Single-Family Credit Risk Transfer
Freddie Mac’s Single-Family CRT programs transfer credit risk away from U.S. taxpayers to global private capital via securities and (re)insurance policies. We founded the GSE Single-Family CRT market when we issued our first Structured Agency Credit Risk (STACR^®) notes in July 2013. In November 2013, we introduced our Agency Credit Insurance Structure^® (ACIS^®) program. Today, CRT serves as the primary source of private capital investment in residential mortgage credit. For specific STACR and ACIS transaction data, please visit Clarity, our CRT data intelligence portal.

About Freddie Mac
Freddie Mac’s mission is to make home possible for families across the nation. We promote liquidity, stability, and affordability in the housing market throughout all economic cycles. Since 1970, we have helped tens of millions of families buy, rent or keep their home. Learn More: Website | Consumers | LinkedIn | Facebook | X | Instagram | YouTube

MEDIA CONTACT: Fred Solomon
703-903-3861
Frederick_Solomon@freddiemac.com

Please read the announcement in PDF

Attachment

• 2026_25_Share_buyback

Following repayment, there are no convertible notes outstanding and RedCloud intends to deregister the unsold ordinary shares under the applicable registration statement to extinguish the related resale overhang

LONDON, Oct. 26, 2026 (GLOBE NEWSWIRE) — RedCloud Holdings plc (Nasdaq: RCT) (“RedCloud” or the “Company”), which is building the AI prediction infrastructure for global FMCG trade, today announced that it has fully repaid the outstanding amounts under the senior convertible notes issued in February 2026 (the “Senior Convertible Notes”) using proceeds from a non-dilutive shareholder loan. Following repayment, the Senior Convertible Notes have been fully satisfied and extinguished and the Company plans to deregister the unsold ordinary shares under the applicable registration statement.

David Sturgeon, Chief Financial Officer of RedCloud, said, “Repaying the Senior Convertible Notes in full strengthens the Company’s capital structure and removes the potential dilution from these instruments. We appreciate the support from our largest shareholder to complete the transaction. Now that we are also implementing steps to reduce our operating cost base, the Company can move forward with a cleaner capital structure.”

About RedCloud

RedCloud Holdings plc (Nasdaq: RCT) builds AI infrastructure for the prediction of FMCG trade. More than $8.4 billion of FMCG transactions have passed through its infrastructure between early 2023 and June 2026, across more than 100,000 customers and 6,700 brands. RedCloud uses this proprietary transaction data to develop RAID (Real-time AI for Distribution), its prediction model for distribution, and deploys its infrastructure and associated products (“RedAI”) either directly or through joint ventures with partners who fund and operate local markets.

RedCloud is a British company registered in London. Justin Floyd is its Founder and Chief Executive Officer. For more information, please visit www.redcloudtechnology.com and connect on LinkedIn.

Forward-Looking Statements

The information in this press release may include forward-looking statements within the meaning of the federal securities laws. These statements include, without limitation, statements regarding the expected improvement in the Company’s capital structure. Words such as “expect,” “project,” “estimate,” “believe,” “anticipate,” “intend,” “plan,” “seek,” “forecast,” “target,” “predict,” “may,” “should,” “would,” “could,” and “will,” the negative of these terms and similar expressions are intended to identify forward-looking statements. Forward-looking statements are based on management’s current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, including, but not limited to, plans to deregister unsold ordinary shares or implementation of steps to reduce the Company’s operating cost base. As a result, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements described in “Cautionary Note Regarding Forward-Looking Statements,” “Item 3. Key Information – D. Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in RedCloud’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission, as well as the Company’s periodic reports and other filings with the Securities and Exchange Commission. RedCloud undertakes no obligation to update or revise these forward-looking statements except as required by law.

Contacts

Investor Relations
investor.relations@redcloudtechnology.com

Media Relations
media@redcloudtechnology.com

Vadadustat demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen

WALTHAM, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) — Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease announced that U.S. Renal Care (USRC), the nation’s largest privately held and fastest-growing kidney care provider, presented data from the Vafseo Outcomes In Center Experience (VOICE) trial during a late-breaking session at American Society of Nephrology Kidney Week 2026 (ASN Kidney Week). The presentation highlighted findings of significantly improved safety outcomes in patients treated with vadadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) dosed three times weekly (TIW) versus an erythropoiesis-stimulating agent (ESA). Additional data showed more stable hemoglobin control and fewer serious adverse events in the patients treated with vadadustat.

In March 2024, Vafseo^® (vadadustat), was approved by the U.S. Food and Drug Administration for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, and it has been available in the U.S. since January 2025. Vafseo is approved for once-daily administration. There are no other oral HIF-PHIs to treat anemia in the market or in development in the U.S.

“The VOICE trial was designed to test the hypothesis that an innovative treatment for anemia in patients on dialysis could deliver more than just hemoglobin management, but rather could deliver clinically meaningful outcomes versus ESA,” said Geoffrey A. Block, M.D., FASN, Associate Chief Medical Officer and Senior Vice President, Clinical Research & Medical Affairs for USRC. “The VOICE trial data demonstrated that treatment with vadadustat resulted in a statistically significant reduction in the primary composite endpoint of all-cause mortality and hospitalization, with the results driven by a reduction in hospitalization, versus patients treated with ESA. Further, we observed that patients treated with vadadustat experienced fewer high hemoglobin excursions and lower ESA rescue versus patients treated with ESA, both clinically meaningful outcomes. We’re extremely pleased that the data validated our understanding of the potential clinical benefit of vadadustat, which we believe positions vadadustat to become a new standard of care. We are grateful to the thousands of patient volunteers who have participated, as well as, the USRC Kidney Research team, investigators, and the staff at participating facilities, all without whom we would not have been able to complete this meaningful trial.”

The VOICE trial enrolled 2,116 patients and was designed as a randomized, open-label, active-controlled, noninferiority trial sponsored by USRC to measure the safety of vadadustat administered TIW versus standard-of-care ESA using a hierarchical composite endpoint of mortality and hospitalization rates. The trial demonstrated a win odds of 1.16 (95% confidence interval (CI) 1.06, 1.28, p=0.0016), establishing non-inferiority and superiority of the primary composite endpoint. Further, the data demonstrated:

• The hospitalization rate was 10% lower in patients treated with vadadustat versus ESA. There was a statistically significant decrease in hospitalization rate with vadadustat versus ESA (111.1 versus 123.1 hospitalizations per 100 patient-years, incidence rate ratio of 0.90 (95% CI, 0.82, 0.99). There was no statistically significant difference between mortality rates with vadadustat versus ESA (8.8% versus 8.8% per 100 patient-years, incidence rate ratio of 1.00 (95% CI 0.72, 1.39).
• Exposure-adjusted serious adverse events were lower with vadadustat versus ESA. Patients treated with vadadustat experienced 121.5 events per 100 patient-years compared to 134.2 events per 100 patient-years for patients treated with ESA.
• Vadadustat improved hemoglobin control versus ESA. High hemoglobin (HgB) excursions were less common in patients treated with vadadustat compared to ESA. The reduction in excursions for patients treated with vadadustat versus ESA were as follows: a 64% reduction in the odds of a HgB above 12 g/dL (29.6% vs. 51.2%, p<0.0001), a 57% reduction in the odds of a HgB above 13 g/dL (6.4% vs. 12.7%, p<0.0001), and 61% reduction in the odds of a HgB above 14 g/dL (1.6% vs. 3.2%, p=0.0044). There was no overall difference in low excursions (below 9, 8, or 7 g/dL). The odds of ESA rescue were 28% less likely with vadadustat versus ESA (44.6% vs. 52.8%, p=0.0006).

About the VOICE Trial

The Vafseo Outcomes In-Center Experience (VOICE) trial, a collaborative trial between U.S. Renal Care and Akebia Therapeutics, is an investigator-initiated, multi-center, randomized, open-label, active-controlled, non-inferiority trial of the safety of vadadustat administered three times per week for the treatment of anemia in in-center hemodialysis patients with end stage kidney disease. The primary endpoint is a composite hierarchical endpoint of all-cause mortality and all-cause hospitalization, analyzed by the win odds method. The secondary endpoints are all-cause hospitalization and all-cause mortality. Please refer to NCT06520826 on www.clinicaltrials.gov for more information about the VOICE trial.

About U.S. Renal Care 

U.S. Renal Care is the largest privately held and fastest-growing dialysis provider in the nation. We partner with nephrologists to care for more than 37,000 people living with kidney disease across 32 states, offering in-center and home dialysis options that support each patient’s unique lifestyle and care needs. U.S. Renal Care leads the dialysis industry with the highest percentage of CMS 4- and 5-star rated centers for patient experience and quality of care. U.S. Renal Care’s Kidney Research team designs and conducts clinical trials, spanning across academic collaboration, investigator-initiated research, industry-sponsored research, and federally-funded research. Since 2000, U.S. Renal Care has grown through clinical excellence, innovation and a shared commitment to improving the lives of people with kidney disease. Visit USRenalCare.com to learn more. 

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Waltham, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

About Vafseo^® (vadadustat) tablets

Vafseo^® (vadadustat) tablets is a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin, increasing hemoglobin and red blood cell production to manage anemia. Vafseo is approved for use in 37 countries.

INDICATION

VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.

Limitations of Use

• VAFSEO has not been shown to improve quality of life, fatigue, or patient well-being.
• VAFSEO is not indicated for use:
  • As a substitute for red blood cell transfusions in patients who require immediate correction of anemia.
  • In patients with anemia due to CKD not on dialysis.

IMPORTANT SAFETY INFORMATION about VAFSEO (vadadustat) tablets

WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, and THROMBOSIS OF VASCULAR ACCESS. 

VAFSEO increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE).  
Targeting a hemoglobin level greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events, as occurs with erythropoietin stimulating agents (ESAs), which also increase erythropoietin levels.  
No trial has identified a hemoglobin target level, dose of VAFSEO, or dosing strategy that does not increase these risks.  
Use the lowest dose of VAFSEO sufficient to reduce the need for red blood cell transfusions.  

CONTRAINDICATIONS  

• Known hypersensitivity to VAFSEO or any of its components  
• Uncontrolled hypertension 

WARNINGS AND PRECAUTIONS

• Increased Risk of Death, Myocardial Infarction (MI), Stroke, Venous Thromboembolism, and Thrombosis of Vascular Access
  A rise in hemoglobin (Hb) levels greater than 1 g/dL over 2 weeks can increase these risks. Avoid in patients with a history of MI, cerebrovascular event, or acute coronary syndrome within the 3  months prior to starting VAFSEO. Targeting a Hb level of greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events. Use the lowest effective dose to reduce the need for red blood cell (RBC) transfusions. Adhere to dosing and Hb monitoring recommendations to avoid excessive erythropoiesis.

• Hepatotoxicity
  Hepatocellular injury attributed to VAFSEO was reported in less than 1% of patients, including one severe case with jaundice. Elevated serum ALT, AST, and bilirubin levels were observed in 1.8%, 1.8%, and 0.3% of CKD patients treated with VAFSEO, respectively. Measure ALT, AST, and bilirubin before treatment and monthly for the first 6 months, then as clinically indicated. Discontinue VAFSEO if ALT or AST is persistently elevated or accompanied by elevated bilirubin. Not recommended in patients with cirrhosis or active, acute liver disease.

• Hypertension
  Worsening of hypertension was reported in 14% of VAFSEO and 17% of darbepoetin alfa patients. Serious worsening of hypertension was reported in 2.7% of VAFSEO and 3% of darbepoetin alfa patients. Cases of hypertensive crisis, including hypertensive encephalopathy and seizures, have also been reported in patients receiving VAFSEO. Monitor blood pressure. Adjust anti-hypertensive therapy as needed.

• Seizures
  Seizures occurred in 1.6% of VAFSEO and 1.6% of darbepoetin alfa patients. Monitor for new-onset seizures, premonitory symptoms, or change in seizure frequency.

• Gastrointestinal (GI) Erosion
  Gastric or esophageal erosions occurred in 6.4% of VAFSEO and 5.3% of darbepoetin alfa patients. Serious GI erosions, including GI bleeding and the need for RBC transfusions, were reported in 3.4% of VAFSEO and 3.3% of darbepoetin alfa patients. Consider this risk in patients at increased risk of GI erosion. Advise patients about signs of erosions and GI bleeding and urge them to seek prompt medical care if present.

• Serious Adverse Reactions in Patients with Anemia Due to CKD and Not on Dialysis
  The safety of VAFSEO has not been established for the treatment of anemia due to CKD in adults not on dialysis and its use is not recommended in this setting. In large clinical trials in adults with anemia of CKD who were not on dialysis, an increased risk of mortality, stroke, MI, serious acute kidney injury, serious hepatic injury, and serious GI erosions was observed in patients treated with VAFSEO compared to darbepoetin alfa.

• Malignancy
  VAFSEO has not been studied and is not recommended in patients with active malignancies. Malignancies were observed in 2.2% of VAFSEO and 3.0% of darbepoetin alfa patients. No evidence of increased carcinogenicity was observed in animal studies.

ADVERSE REACTIONS

• The most common adverse reactions (occurring at ≥ 10%) were hypertension and diarrhea.

DRUG INTERACTIONS

• Iron supplements and iron-containing phosphate binders: Administer VAFSEO at least 1 hour before products containing iron.
• Non-iron-containing phosphate binders: Administer VAFSEO at least 1 hour before or 2 hours after non-iron-containing phosphate binders.
• BCRP substrates: Monitor for signs of substrate adverse reactions and consider dose reduction.
• Statins: Monitor for statin-related adverse reactions. Limit the daily dose of simvastatin to 20 mg and rosuvastatin to 5 mg.

USE IN SPECIFIC POPULATIONS

• Pregnancy: May cause fetal harm. A pregnancy exposure registry is available to monitor outcomes in women exposed to VAFSEO during pregnancy. Report pregnancies to 1-844-445-3799.
• Lactation: Breastfeeding not recommended until two days after the final dose.
• Hepatic Impairment: Not recommended in patients with cirrhosis or active, acute liver disease.

Please note that this information is not comprehensive. Please click here for the Full Prescribing Information, including BOXED WARNING and Medication Guide.

Forward-Looking Statements

Statements in this press release regarding Akebia Therapeutics, Inc.’s (“Akebia’s”) strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and include, but are not limited to: statements made by Geoffrey A. Block in this press release, including the hypothesis that vadadustat could deliver hemoglobin management as well as clinically meaningful outcomes versus ESA, beliefs that patients experiencing fewer high hemoglobin excursions and lower ESA rescue when treated with vadadustat versus ESA as observed in the VOICE trial represent clinically meaningful outcomes, beliefs and understandings regarding the potential clinical benefit of vadadustat and the extent it is positioned to become a new standard of care.

The terms “intend,” “believe,” “plan,” “goal,” “potential,” “anticipate,” “estimate,” “target,” “predict,” “expect,” “future,” “may,” “will,” “could,” “continue,” derivatives of these words, and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors, including, but not limited to, risks associated with: the potential therapeutic benefits, safety profile, and effectiveness of vadadustat; risks and uncertainties related to Akebia’s ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials and the timing of such preclinical studies and clinical trials; the results of Akebia’s preclinical studies and clinical trials, including that initial, preliminary, interim or retrospective data, analysis or results may not be replicated in, or predictive of, final analyses or results of future preclinical or clinical data, analyses or results or that such analysis or results may not support further development of such product candidates; Akebia’s ability to initiate and enroll patients in its clinical trials; decisions made by health authorities, such as the FDA, with respect to regulatory filings and other interactions; the potential demand and market potential and acceptance of, as well as coverage and reimbursement related to Akebia’s commercial products, including estimates regarding the potential market opportunity; the competitive landscape for Akebia’s commercial products, including generic entrants and the timing thereof; Akebia’s ability to obtain and maintain patent protection on its products and product candidates, and to successfully defend these patents against third-party challenges; Akebia’s ability to attract and retain qualified personnel; Akebia’s ability to achieve and maintain profitability and to maintain operating expenses consistent with its operating plan; Akebia’s revenue and that its financial results from prior periods may not be indicative of future results; manufacturing, supply chain and quality matters and any recalls, write-downs, impairments or other related consequences or potential consequences; early termination of any of Akebia’s collaborations; and changes in the geopolitical environment and uncertainty surrounding U.S. trade policy on tariffs. Other risks and uncertainties include those identified under the heading “Risk Factors” in Akebia’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC), and other filings that Akebia may make with the SEC in the future. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and, except as required by law, Akebia does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this press release.

Akebia Therapeutics^® and Vafseo^® are registered trademarks of Akebia Therapeutics, Inc.

Akebia Therapeutics Contact

Mercedes Carrasco
mcarrasco@akebia.com